From Cresset Jun 4 2026 Are you working on data-sparse or novel targets? Join us June 11 th to learn how Avammune progressed from early concepts to trial-stage candidates in this space. Register here to secure your place. In 45 minutes, you'll cover: Real-world approaches that worked (and what didn’t) Why generative AI alone wasn’t enough in new chemical space Case studies advancing candidates despite limited data, including: ENPP1 inhibitor to restore cGAS–STING pathway activation ADAR1 p150